CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤的抗 BCMA 新型疗法
英文原题：Anti-BCMA novel therapies for multiple myeloma.
查看英文原题
Anti-BCMA novel therapies for multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤治疗近期进展提高了缓解深度并最终改善生存，但患者预后仍较差。BCMA 抗原在骨髓瘤细胞中高表达，是新型疗法的靶点。目前已有或正在开发多种通过不同机制靶向 BCMA 的药物，包括双特异性 T 细胞衔接器、抗体药物偶联物和 CAR-T 细胞。对于既往接受过多线治疗的多发性骨髓瘤患者，靶向 BCMA 的免疫疗法已显示出良好的疗效和安全性。本文综述骨髓瘤抗 BCMA 靶向治疗的近期进展，特别关注目前可用的药物。
展开英文摘要原文
Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development.
Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.
论文信息
- 作者
- Sammartano V、Franceschini M、Fredducci S、Caroni F、Ciofini S、Pacelli P、Bocchia M、Gozzetti A
- 第一作者单位
- Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena 53100, Italy.Italy
- 通讯作者单位
- Authors share last co-authorship.
- 文献类型
- 综述
- 期刊
- Cancer drug resistance (Alhambra, Calif.)2023
- 原文标识
- PubMed 37065871 · DOI 10.20517/cdr.2022.138
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →